Evidence map›Paper›PMID 35042311›Full record

ArticleAsian journal of andrology

Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate.

Qi-Liang Teng, Xin-Rui Yang, Shuang Wen, Zhi-Hong Dai, Hong-Long Wang, Tian-Qing Liu, Liang Wang, Bo Fan, Zhi-Yu Liu

Open access · goldAbstract read
In one paragraph

Article in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Qi-Liang TengDepartment of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Xin-Rui YangDepartment of Clinical Imaging, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Shuang WenDepartment of Pathology, Dalian Friendship Hospital, Dalian 116001, China.
Zhi-Hong DaiDepartment of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Hong-Long WangDepartment of Pathology, Dalian Friendship Hospital, Dalian 116001, China.
Tian-Qing LiuDepartment of Pathology, Dalian Friendship Hospital, Dalian 116001, China.
Liang WangDepartment of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Bo FanDepartment of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Zhi-Yu LiuDepartment of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Dalian Medical University · CNYili Friendship Hospital · CNSecond Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary signet ring cell carcinoma (SRCC) of the prostate is a rare neoplasm. However, its potential tumorigenic mechanism, clinicopathological features, and prognostic outcome have not been systematically described. To determine the pathogenic mechanism, we detected distributions of programmed cell death-ligand 1 (PD-L1), programmed death 1 (PD-1), and cellular components in the tumor microenvironment, including tumor-infiltrating lymphocytes (CD4 and CD8), tumor-associated macrophages (TAMs; CD163 and CD68), and tumor-associated fibroblasts (vimentin and alpha-smooth muscle actin [α-SMA]), in tumor tissues from four patients with primary prostatic SRCC compared with corresponding adjacent tissues and tumor tissues from 30 patients with prostate adenocarcinoma (PCa) by immunohistochemical staining. We found higher expression of PD-L1, CD163, and CD68 in primary SRCC specimens than that in both corresponding adjacent nontumor specimens and PCa specimens with different Gleason scores, indicating that TAMs may participate in the malignant biological behavior of primary SRCC of the prostate. For further analysis, we searched electronic journal databases and Surveillance, Epidemiology, and End Results (SEER) to identify 200 eligible patients including our four cases. According to Kaplan-Meier survival curve analysis, patients <68 years old, with radical prostatectomy (RP), Gleason score of 7-8, and lower clinical stage had longer overall survival (OS). Moreover, Cox multivariate analysis indicated that race (hazard ratio [HR] = 1.422), surgical approach (HR = 1.654), and Gleason score (HR = 2.162) were independent prognostic factors for OS. Therefore, primary SRCC of the prostate represents a distinct and aggressive subtype of prostate cancer associated with a higher distribution of PD-L1 and TAMs, which warrants further clinical investigation.

Indexed as

Carcinoma, Signet Ring CellProstatic NeoplasmsAgedB7-H1 AntigenHumansLymphocytes, Tumor-InfiltratingMalePrognosisProstateTumor MicroenvironmentB7-H1 Antigenclinical featuresimmunohistochemistryinfiltrating immune cellsprimary signet ring cell carcinoma of the prostatetumor microenvironment

Identifiers

PMID35042311
PMCPMC9491031
OpenAlexW4206457954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.